Developing Drugs to Neglected Tropical Diseases Waldir Ventura Filho IEEE Number: 92757194 President of IEEE CS UFABC Student Chapter Santo André – São Paulo – Brazil

Neglected Tropical diseases Group of parasitic and bacterial diseases Affect more than 1.5 billion people worldwide Related to poverty and lack of access to minimum health and sanitation Affect physical and cognitive development Examples: barber bug fever, ascariasis, elephantiasis, leishmaniasis

Drugs Overview Drugs for NDT did not evolved as the same of heart diseases, which affects rich countries as well The risk of investment would be high because of poor countries Rigorous market analysis for new drugs because is related to the welfare of human beings Accuracy needs to be high since it deals with lives By the year 2010 more than half drugs introduced to the market was only na incremental innovation

Drugs Research R&D for drugs consists of a long chain from basic research, pass through clinical analysis before the manufactuiring and launch According to FDA, development of a new drug takes 10 to 15 years Scientific community takes effort in researches Limitation in the public’s purchasing power limitates the production

The solution Create a new business model Integrate drug innovation research with producers Contemplate the whole process Development Clinical Analysis Production Launch Contemplate demand of NTD

Use The Open Intellectual Property Movement How make it happen Analysis of IEEE CS 2022 report Understand the 23 technologies in 2022 Evaluation of technologies Use The Open Intellectual Property Movement

The project Player 4 Player 1 Player 3 Player 2 Colaborative platform Join forces of each part of the process Four stages of the production Four playerrs on the platform Player 4 Player 1 Player 3 Player 2

Players Player 1: Research institutions Responsible for creating a new molecule Scientists, Universities Professors Relationship with existing researches Co-creating ideas Player 2: Institutes of Clinical Analysis Responsible for clinical analysis Whole process of clinical analysis Companies with know-how in the area

Players Player 3: Pharmaceutical Companies Responsible for the production Produce and launch the drug to the market Companies able to produce on a large scale Accredited Company Player 4: Manager (may be the World Health Organization) Manage the entire system Integrate all the players Follow and moderate the steps of the work

Platform Advantages Managed by WHO Selection of best players Reduce time of production Exclude the lack between the players Integrated idea Ease of communication Co-creation

Image References http://3.bp.blogspot.com/- anoJqdIDJIE/Tocsna77ldI/AAAAAAAAALY/gZob2qvfRfM/s1600/Picture2.png